Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 22;13(Suppl 1):S39-S43.
doi: 10.1093/inthealth/ihaa077.

The role of medicine donations in the global programme for the elimination of lymphatic filariasis

Tijana Williams  1 , Rachel Taylor  2 , Minne Iwamoto  1 , Takayuki Hida  3 , Fabian Gusovsky  4
Affiliations

The role of medicine donations in the global programme for the elimination of lymphatic filariasis

Tijana Williams et al. Int Health. .

Erratum in

Abstract

World Health Assembly Resolution 50.29, adopted in 1997, committed the World Health Organization (WHO) and its member states to eliminate lymphatic filariasis (LF) as a public health problem. In 2000, to support this ambitious goal and the health ministries in the >70 LF-endemic countries, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) was created. The resulting WHO elimination strategy consists of two main components: to stop the spread of infection by interrupting transmission and to alleviate the suffering of affected populations (by controlling morbidity). The GPELF has brought together a broad global partnership of public and private actors, including three pharmaceutical companies with headquarters in three different continents. The medicine donations programmes from GlaxoSmithKline, MSD (trade name of Merck & Co., Kenilworth, NJ, USA) and Eisai have enabled significant achievements during the first 20 y of the GPELF and are positioned to provide essential contributions to the GPELF's goals for the next decade. As we celebrate the progress towards LF elimination during the GPELF's first 20 y, this article reflects on the factors that led to the creation of the three donation programmes, the contributions these programmes have made and some lessons learned along the way. We close by emphasizing our continued commitments to LF elimination and perspectives on the next decade.

Keywords: drug donation; lymphatic filariasis; neglected tropical diseases.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Donated medicines for the elimination of LF, 1999–2019 (Eisai, GSK, MSD).
Figure 2.
Figure 2.
Distribution of LF and status of Preventative Chemotherapy (PC) in endemic countries.
See this image and copyright information in PMC

References

    1. Otsuji Y. History, epidemiology and control of filariasis. Trop Med Health. 2011;39(1 Suppl 2):3–13. - PMC - PubMed
    1. World Health Organization . Global programme to eliminate lymphatic filariasis: progress report. Wkly Epidemiol Rec. 2001;76(20):149–53.
    1. World Health Organization . Lymphatic filariasis: global programme to eliminate lymphatic filariasis. Available from: http://www.who.int/lymphatic_filariasis/eliminationprogramme/ [accessed 10 August 2020].
    1. Ismail MM, Jayakody RL, Weil GJ et al. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg. 1998;92(1):94–7. - PubMed
    1. Wamaea CN, Njengaa SM, Ngugi BM et al. Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters. Acta Trop. 2011;120(Suppl 1):S33–8. - PubMed